Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine

Nicholas Kitchin*, Joanna Southern, Rhonwen Morris, Raymond Borrow, Anne Fiquet, Florence Boisnard, Stéphane Thomas, Elizbeth Miller

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

This open-label, randomised, controlled study examined antibody persistence following infant vaccination at 2, 3 and 4 months of age with either an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Haemophilus influenzae type b (DT5aP-IPV-Hib; Pediacel®) or a whole-cell pertussis (DTwP//Hib + oral poliomyelitis vaccine [OPV]) combination vaccine, given concomitantly with meningococcal serogroup C conjugate (MCC) vaccine, followed by a Hib booster at approximately 15 months of age. Immune responses were sustained to 3.5-4.5 years of age for all antigens contained in Pediacel. Administration of an acellular pertussis-containing quadrivalent pre-school booster (Td5ap-IPV; Repevax®), with or without measles, mumps and rubella (M-M-R™II) vaccine, induced robust antibody responses indicative of protection, regardless of the vaccine used for the primary series. Reactogenicity of Repevax was acceptable and consistent with previous experience.

Original languageEnglish
Pages (from-to)5096-5102
Number of pages7
JournalVaccine
Volume27
Issue number37
DOIs
Publication statusPublished - 13 Aug 2009

Keywords

  • Acellular pertussis combination vaccine
  • Immunogenicity and safety
  • Pre-school booster

Fingerprint

Dive into the research topics of 'Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine'. Together they form a unique fingerprint.

Cite this